Condition: Metastatic Thyroid Cancer · Sponsor: University of Michigan Rogel Cancer Center
This study will be a non-randomized pilot trial using Cyclophosphamide and Sirolimus for the treatment of metastatic differentiated thyroid cancer. Patients will be treated with Sirolimus 4 mg, PO, days 1-28 as well as Cyclophosphamide 100 mg, PO, days 1-5 and 15-19. Cycle length will be 28 days. Patients will be monitored closely for toxicity and undergo imaging to evaluate efficacy once every 2 cycles.
This description comes directly from the study's public registry record.
Cancer AnswerLine · 1-800-865-1125 · canceranswerline@umich.edu
Paul Swiecicki, M.D. · pswiecic@med.umich.edu
Always discuss trial participation with your own doctor first.
| University of Michigan Cancer Center | Ann Arbor, Michigan, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03099356